|
|
| Home | Stock Market Blogs | Financial Tools | Sign Up Free | |
| Genelabs Technologies, Inc. | |
||||||||||||||||||||||||||||||||||||||||||||||||||||
| Genelabs Technologies, Inc. | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GNLB | Last: $1.29 ($0.00) | Volume: 0 | Last Trade: 1/8/2009 6:07:07 AM | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Today
Today | Last 7 Days | 1 Month | 3 Month | 6 Month | 1 Year |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
| Genelabs Technologies, Inc. Profile | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Genelabs Technologies is a biopharmaceutical company that discovers and develops pharmaceutical products to improve human health. Co.'s drug discovery programs are focused on new treatments for infection with the hepatitis C virus. Co. also seeks to identify compounds that have an advantage over potential competitive compounds in potency, safety and/or pharmacokinetic properties. Also, Co. has two separate development-stage projects: Prestaratm (prasterone), an investigational drug for systemic lupus erythematosus, referred to as systemic lupus erythematosus or lupus, and an investigational vaccine for hepatitis E virus that is being developed by GlaxoSmithKline under a license from Co. | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Genelabs Technologies, Inc. News & Press Releases | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|
GlaxoSmithKline Announces Waiver of a Condition to the Tender Offer for Genelabs Technologies, Inc. LONDON and PHILADELPHIA , Dec. 3 /PRNewswire-FirstCall/ -- GlaxoSmithKline (LSE/ GSK ) announced today that it is waiving a condition relating to a pending lawsuit in th... [more] GlaxoSmithKline to Acquire Genelabs Technologies to Increase Focus on Novel Small Molecule Therapies PHILADELPHIA , Oct. 29 /PRNewswire-FirstCall/ -- GlaxoSmithKline ( GSK ) ( GSK ) and Genelabs Technologies, Inc. ( GNLB ) announced today that they have entered into a definiti... [more] Genelabs to Present at the Susquehanna SIGnificant Investment ... PR-Inside.com (Pressemitteilung): Genelabs to Present at the Susquehanna SIGnificant Investment ... , Austria - Feb 29, 2008 www.genelabs.com - Genelabs Technologies, Inc. ( NASDAQ:GNLB ) announced today that its Chief Financial Officer Fred Driscoll will present a com Genelabs to Present at the Ad-Hoc-News (Pressemitteilung): , Germany - Feb 29, 2008 Genelabs Technologies, Inc. ( NASDAQ:GNLB ) announced today that its Chief Financial Officer Fred Driscoll will present a company update at the Susquehanna ... BUYINS.NET: GNLB, ORBC, SGLP, CCNI, ILNS, SWVC Have Also Been ... Trading Markets (press release): BUYINS.NET: GNLB, ORBC, SGLP, CCNI, ILNS, SWVC Have Also Been ... , CA - Feb 26, 2008 Genelabs Technologies Inc. ( NASDAQ: GNLB | news | PowerRating | PR Charts ) a biopharmaceutical company, engages in the discovery and development o Genelabs Technologies to Present at the BIO CEO & Investor Conference PR Newswire (press release): Genelabs Technologies, Inc. ( Nasdaq: GNLB ) announced today that its Chief Financial Officer Fred Driscoll will present a company ... Genelabs Announces Publication in New England Journal of Medicine ... Drug Newswire (press release): Genelabs Technologies, Inc. ( NASDAQ:GNLB ) today announced publication of the results of a clinical ... Genelabs Tech (GNLB) Announces Publication in New England Journal ... StreetInsider.com (subscription): Genelabs Tech (GNLB) Announces Publication in New England Journal ... , MI - Mar 1, 2007 Genelabs Technologies, Inc. ( Nasdaq: GNLB ) announced publication of the results of a clinical trial with an investigational hepatitis E virus (H Genelabs Technologies (GNLB) Announced $10M Private Placement StreetInsider.com (subscription): , MI - Feb 9, 2007 Genelabs Technologies, Inc. ( Nasdaq: GNLB ) entered into an agreement for the sale of approximately 5.8 million shares of its common stock and warrants to ... Genelabs Technologies Announces Sale of Equity in Taiwan-Based ... Drug Newswire (press release): Genelabs Technologies, Inc. ( NASDAQ:GNLB ) announced today that it has sold substantially all of its remaining equity in ... Genelabs sells stake in Taiwan biotech San Francisco Business Times: Genovate Biotechnology Co. -- in 1995. Genelabs sold 7.1 million shares of ... |
|||||||||||||||||||||||||||||||||||||||||||||||||||||
| Home | Blogs | Savings Calculator | Tools | Contact Us | Disclosure | Site Map | Sign Up | Copyright © 2010 SmallCapWatch, LLC. |
| Never invest based soley on information from this website or our e-mail and IM alerts | |
